Mr. Bill Jackson reports

VECTOR SCIENCE & THERAPEUTICS ENTERS THREE-YEAR DEVELOPMENT AND MANUFACTURING AGREEMENT WITH MPP GROUP LLC

Vector Science and Therapeutics Corp. has entered into a development and manufacturing agreement with MPP Group LLC, a contract development and manufacturing organization based in Mequon, Wis., to develop and manufacture pharmaceutical-grade peptides and to manufacture drug delivery devices developed by Vector.

The three-year agreement co-locates compound formulation, analytical testing and Vector's proprietary transdermal delivery platform within a single Food and Drug Administration-registered, cGMP-compliant facility, accelerating development cycles and ensuring quality from formulation through delivery. The arrangement supports the company's entry into the $80.8-billion peptide market with pharmaceutical-grade, shelf-stable formulations.

Key highlights:

• FDA-registered, cGMP facility access: MPP's Mequon, Wis., facility represents approximately $6-million in capital expenditure that Vector avoids duplicating.
• Twenty-two novel peptide formulations: Vector and MPP will jointly develop shelf-stable formulations (up to 24 months), including 14 peptides recently returned to eligibility for compounding under physician supervision following removal from the FDA Category 2 list.
• Three-year term, Vector-owned equipment: Vector funds peptide-manufacturing equipment dedicated exclusively to its products and retains ownership, with the right to take possession in the event of termination.
• Eight billion 800 hundred million peptide market entry: Pharmaceutical-grade products for physician-supervised use, supporting buildout of Vector's distribution channel for its proprietary transdermal delivery technology.

Under the agreement, Vector and MPP will collaborate on novel peptide formulation development, joint development of purity and potency test methods, and aseptic manufacturing of pharmaceutical-grade peptides in defined milligram quantities. The parties will jointly develop novel formulations for 22 peptides designed to be shelf-stable for up to 24 months. Fourteen of these peptides were recently removed by the FDA from the Category 2 list.

Purity and potency test methods developed jointly by Vector and MPP will be held as trade secrets for the parties' exclusive mutual use. Formulation development and initial manufacturing are scheduled to commence in May, 2026.

"Access to an FDA drug registered, cGMP manufacturing facility is foundational for any company serious about delivering pharmaceutical-grade therapeutics. This agreement gives Vector that foundation right here in Wisconsin and positions the company to bring the discipline of regulated drug manufacturing to its peptide portfolio from day one," said Tommy Thompson, chairman, Vector Science and Therapeutics, and former U.S. secretary of health and human services.

"This agreement gives Vector direct control over the equipment, the formulations and the manufacturing process with a pharmaceutical-grade partner located in our own backyard. It is the foundation on which we will build our distribution channel for Vector's transdermal delivery technology," said Bill Jackson, chief executive officer, Vector Science and Therapeutics.

"Peptide therapeutics have demonstrated significant clinical potential across a growing number of indications, but their broader adoption has been limited in part by challenges in formulation stability, delivery precision and route of administration. This agreement positions Vector to begin addressing those challenges by developing shelf-stable, pharmaceutical-grade formulations within a cGMP environment, an essential step toward our goal of enabling clinician-directed peptide delivery with improved site specificity. We look forward to generating the formulation and stability data needed to advance these programs," said Dr. Brad Worthington, chief medical officer, Vector Science and Therapeutics.

About Vector Science and Therapeutics Corp.

Vector, headquartered in Mequon, Wis., develops novel biomechanical devices and active localized drug delivery platforms to equip clinicians with site-directed interventions where precision matters and systemic risks are unacceptable. The company's shares are listed on the TSX Venture Exchange under the symbol PAIN.

We seek Safe Harbor.